Akari Therapeutics (AKTX) Assets Average (2012 - 2026)
Akari Therapeutics (AKTX) reported Assets Average of $40.9 million for Q1 2026, down 19.44% on a YoY basis from $50.8 million in Q1 2025, and down 12.32% sequentially from $46.6 million in Q4 2025.
Akari Therapeutics (AKTX) Assets Average (2012 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 13 years of Assets Average data on file, last reported at $40.9 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 19.44% year-over-year to $40.9 million; the trailing twelve-month figure through Mar 2026 stood at $40.9 million (down 19.44% YoY), and the FY2025 full-year result was $49.2 million, up 79.28% from the prior year.
- Assets Average fell to $40.9 million in Q1 2026, from $46.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $50.9 million in Q2 2025 to a low of $3.6 million in Q1 2024.
- A 4-year average of $28.8 million and a median of $33.8 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average soared 1324.46% in 2025 and retreated 19.44% in 2026, its largest moves.
- Tracing AKTX's Assets Average over 4 years: stood at $12.7 million in 2022, then surged by 109.17% to $26.6 million in 2024, then jumped by 75.0% to $46.6 million in 2025, then slipped by 12.32% to $40.9 million in 2026.
- Business Quant data shows AKTX's Assets Average at $40.9 million in Q1 2026, $46.6 million in Q4 2025, and $48.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.30 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 5.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.89 Mn |
| Dec 31, 2025 | 46.63 Mn |
| Sep 30, 2025 | 48.14 Mn |
| Jun 30, 2025 | 50.94 Mn |
| Mar 31, 2025 | 50.76 Mn |
| Dec 31, 2024 | 26.65 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 3.92 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2022 | 12.74 Mn |
| Dec 31, 2021 | 13.13 Mn |
| Dec 31, 2020 | 14.15 Mn |
| Sep 30, 2020 | 14.07 Mn |
| Jun 30, 2020 | 12.07 Mn |
| Mar 31, 2020 | 8.08 Mn |
| Dec 31, 2019 | 8.37 Mn |
| Sep 30, 2019 | 7.44 Mn |
| Jun 30, 2019 | 6.42 Mn |
| Mar 31, 2019 | 8.13 Mn |
| Dec 31, 2018 | 18.54 Mn |